Illustrative image – not actual.Hikal Ltd intends to strengthen its presence in the pharmaceuticals sector. Further, the company has temporarily put on hold its plans to diversify into biotechnology sector.
The company plans to increase its activities in the active pharmaceutical ingredients (APIs) and contract research.
Hikal is also installing thermal oxidiser incinerators at its Panoli manufacturing facility in Gujarat.
Meantime, Hikal has completed an investment programme of Rs.30 crore at the R&D Centre Bangalore, which was acquired from Wintac (earlier Recon Ltd). The R&D Centre and APIs are due for inspection by US-FDA in early 2003 after which, exports to the lucrative US market would commence.
